<ѻýҕl>Cancer Immunotherapy Tied to Severe COVID-19 Outcomesѻýҕl> Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<ѻýҕl>Worse Blood Cancer Outcomes in Hispanicsѻýҕl> Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<ѻýҕl>Endoscopic Procedure Wins in Early Stomach Cancerѻýҕl> In the U.S. and Canada, curative resection high, recurrence low -- and learning curve steep Jun 22, 2020
<ѻýҕl>Combination Ups Survival in Older AML Patientsѻýҕl> Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone Jun 17, 2020
<ѻýҕl>Biologic Effective in Light Chain Amyloidosisѻýҕl> Anti-CD38 therapy added to conventional regimen boosts PFS in trial Jun 16, 2020
<ѻýҕl>Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trialѻýҕl> Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases Jun 15, 2020
<ѻýҕl>New Standard for Relapsed/Refractory Multiple Myeloma?ѻýҕl> Triplet regimen significantly extended median PFS versus doublet in IKEMA study Jun 15, 2020
<ѻýҕl>High Marks for CAR T Cells in R/R Myelomaѻýҕl> Response rates of 70-100% with BCMA-targeted products for heavily treated disease Jun 03, 2020
<ѻýҕl>Second Surgery Gets OS Win in Recurrent Ovarian Cancerѻýҕl> Survival improved by nearly 8 months with cytoreductive surgery at first relapse Jun 02, 2020
<ѻýҕl>Early Palliation: Boon for AML Patients on Intensive Chemoѻýҕl> Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
<ѻýҕl>Pembrolizumab May Help in Triple-Negative Breast Cancerѻýҕl> Upfront therapy extends progression-free survival in metastatic disease, study shows Jun 01, 2020
<ѻýҕl>Surgery for Metastatic Breast Cancer Fails to Boost Overall Survivalѻýҕl> Cumulative data, though, don't rule out benefit for selected patients with de novo stage IV disease Jun 01, 2020
<ѻýҕl>Add-On Tucatinib Ups Survival in Breast Cancer With Brain Metsѻýҕl> TKI plus trastuzumab-capecitabine reduced risk of death by nearly half Jun 01, 2020
<ѻýҕl>VRd Still Reigns in Newly Diagnosed Myelomaѻýҕl> KRd fails to prove superiority in head-to-head trial Jun 01, 2020
<ѻýҕl>CAR T-Cell Therapy Impresses in Indolent NHLѻýҕl> Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting May 31, 2020
<ѻýҕl>Oral ADT Slashes Heart Risk in Advanced Prostate Cancerѻýҕl> Novel GnRH antagonist has potential to be new standard, says researcher May 30, 2020
<ѻýҕl>Studies Make Case for Hormonal Therapy in nmCRPCѻýҕl> Prolonged survival with three different androgen signaling inhibitors May 30, 2020
<ѻýҕl>HCQ Linked to Harm in Cancer Patientsѻýҕl> Combination with azithromycin associated with three-fold risk of mortality, registry study shows May 28, 2020
<ѻýҕl>COVID-19 in Thoracic Cancer Patients a Killerѻýҕl> Most cancer patients hospitalized May 28, 2020
<ѻýҕl>New First-Line Standard in Metastatic Bladder Cancerѻýҕl> "High bar to beat" as avelumab maintenance improves median survival by over 7 months May 28, 2020
<ѻýҕl>Paradigm Shift Coming for Early NSCLC?ѻýҕl> Postoperative osimertinib doubles DFS in patients with stages Ib-IIIa EGFR+ lung cancer May 28, 2020
<ѻýҕl>End of Life and COVID-19; DCIS Doubles Cancer Risk; Training for 'Bad News'ѻýҕl> News, features, and commentary about cancer-related issues May 28, 2020
<ѻýҕl>New Clue to Anti-PD-L1 Activity in Breast Cancer?ѻýҕl> Survival benefit with durvalumab in patients with PDL1 copy number alteration May 26, 2020
<ѻýҕl>Biologics Don't Increase Melanoma Risk... Probablyѻýҕl> Meta-analysis offers some reassurance, but leaves room for doubt May 20, 2020
<ѻýҕl>Avelumab Flops Again in Ovarian Cancerѻýҕl> Another negative phase III trial, now in the first-line setting May 19, 2020
<ѻýҕl>PARP Inhibitors Still Work in HRD-Low Ovarian Cancerѻýҕl> In VELIA, homologous recombination deficiency score prognostic but not predictive May 14, 2020
<ѻýҕl>KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancersѻýҕl> Nearly 7-month PFS boost in patients with KRAS mutations May 11, 2020
<ѻýҕl>Five Days of G-CSF Adequate for Breast Cancer Chemoѻýҕl> Rate of chemotherapy-induced febrile neutropenia similar to 7- to 10-day regimen May 08, 2020
<ѻýҕl>Face-Aging Selfies Help Modify Risky Skin Behaviors for Teensѻýҕl> Trial looked at effects of a free "UV-selfie" app May 07, 2020
<ѻýҕl>BMI, Weight Change Linked to Prostate Ca Outcomesѻýҕl> Gain or loss of body weight both show risk May 07, 2020
<ѻýҕl>Blood Test Promising as Colorectal Cancer Screenѻýҕl> In early study, better numbers than with current alternatives to colonoscopy May 07, 2020
<ѻýҕl>Ranitidine Cancer Risk: Health Records Offer Reassuranceѻýҕl> Huge study finds no indication that nitrosamine contamination affected real-world outcomes May 05, 2020
<ѻýҕl>Honing Chemo Use in Small Breast Tumorsѻýҕl> Clearest survival benefit for 8-10 mm tumors in HR/HER2-positive disease May 03, 2020
<ѻýҕl>Nivolumab-Based Tx Effective in Early, Unfavorable Hodgkin'sѻýҕl> Interim results showed high CR rates and almost 100% PFS, OS at 12 months May 01, 2020
<ѻýҕl>6-Week Keytruda Safe, Effective in Melanomaѻýҕl> Schedule gets FDA approval for all adult indications Apr 30, 2020
<ѻýҕl>Talzenna Misses OS Endpoint in BRCA-Positive Breast Cancerѻýҕl> But PARP inhibitor improved patient-reported outcomes over standard therapy Apr 29, 2020
<ѻýҕl>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancersѻýҕl> Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<ѻýҕl>Anti-PD-L1 Plus PARP Inhibitor Ups Response in Breast Cancerѻýҕl> Add-on treatment superior to chemo alone, but questions remain about cost, toxicity Apr 28, 2020
<ѻýҕl>Triplet Succeeds in BRAF-Mutant Melanomaѻýҕl> Immunotherapy plus BRAF/MEK inhibition boosts PFS over targeted agents alone Apr 27, 2020